Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intradigm announces allowance of RNA interference patent
The allowed subject matter is not only focused on claims to siRNAs but also includes specific coverage for micro RNAs (miRNAs), miRNA precursors, primary miRNA transcripts and short
The allowed subject matter is not only focused on claims to siRNAs but also includes specific coverage for micro RNAs (miRNAs), miRNA precursors, primary miRNA transcripts and short
Johnson & Johnson’s (J&J) new EZ Steer ThermoCool catheter, manufactured by Biosense Webster, is a unique bi-directional catheter with an open irrigation tip available in the EU. The
The agreement supports a multi-year relationship aiming to make efficient use of the best scientific expertise from both Columbia University Medical Center and AstraZeneca to find optimal treatments
The acquisition will occur through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of several successive milestones with Actimis’s leading
Synergetics plans to incorporate Medimold’s plastic injection molding technology into its operations by moving currently machined parts to the Medimold platform. Annual initial cost savings resulting from the
David McWilliams, the former CEO, will continue to serve on the board of directors and in a consulting capacity during the transition. Mr McWilliams has served as president,
The company has requested priority review of its US application and, if granted, Mozobil could be approved by the end of 2008. European approval is expected in 2009.
Under terms of the agreement, MonoSol Rx will receive milestone payments prior to commercial launch and sales-based milestones that could total $23.5 million as well as payments for
The Phase I trial is expected to enroll up to 63 patients with advanced metastatic cancer who have failed or are intolerant of standard therapy. Patients will receive
The patent was issued to Eurand, the developer of Amrix, and expires on February 26, 2025. In 2007, Cephalon acquired an exclusive license from Eurand to market Amrix